BFM
ANIP icon

Boothbay Fund Management’s ANI Pharmaceuticals ANIP Stock Holding History

Boothbay Fund Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.17M Buy
41,200
+18,600
+82% +$1.45M 0.04% 455
2025
Q4 		$1.78M Buy
+22,600
New +$1.96M 0.03% 597

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Boothbay Fund Management's ANIP Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in ANI Pharmaceuticals (ANIP) in Q1 2026: 40,743 shares worth $3.13M. The stake represents 0.04% of the portfolio and ranks #459 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in ANIP as recently as Q4 2019.

Boothbay Fund Management first reported a position in ANIP in Q4 2019 and has held it in 2 quarters since. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Boothbay Fund Management held 40,743 shares of ANI Pharmaceuticals worth $3.13M as of Q1 2026.
  • ANI Pharmaceuticals was a new Boothbay Fund Management position in Q1 2026.
  • ANI Pharmaceuticals made up 0.04% of Boothbay Fund Management's portfolio in Q1 2026, its #459 holding.
  • Boothbay Fund Management first reported a position in ANI Pharmaceuticals in Q4 2019 and has held it in 2 quarters since.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.